Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Cost-Effectiveness and Cost-Utility Analysis of Type-2 Diabetes Screening in Pharmacies in Iran Publisher



Amirsadri M1, 2 ; Torkpour E2
Authors

Source: Research in Pharmaceutical Sciences Published:2023


Abstract

Background and purpose: Several studies have shown the effectiveness of screening programs in decreasing the costs and disutility of type-2 diabetes and related complications. As there is a growth in the incidence of type-2 diabetes amongst the Iranian population, the cost-effectiveness of performing type-2 diabetes screening tests in community pharmacies of Iran was evaluated in this study from the payer's perspective. The target population consisted of two hypothetical cohorts of 1000 people 40 years of age without a prior diagnosis of diabetes, for the intervention (screening test) and no-screening groups. Experimental approach: A Markov model was developed to evaluate the cost-effectiveness and cost-utility of a type-2 diabetes screening test in community pharmacies in Iran. A 30-year time horizon was considered in the model. Three screening programs with 5-year intervals were considered for the intervention group. The evaluated outcomes were quality-adjusted life-years (QALYs) for cost-utility-analysis and life-years-gained (LYG) for cost-effectiveness-analysis. To examine the robustness of the results, one-way and probabilistic-sensitivity analyses were applied to the model. Findings/Results: The screening test represented both more effects and higher costs. The incremental effects in the base-case scenario (no-discounting) were estimated to be 0.017 and 0.0004 (approximately 0) for QALYs and LYG, respectively. The incremental cost was estimated to be 2.87 USD/patient. The estimated incremental-cost-effectiveness ratio was 164.77 USD/QALY. Conclusion and implications: This study indicated that screening for type-2 diabetes in community pharmacies of Iran could be considered highly cost-effective, as it meets the WHO criteria of the annual GDP per capita ($2757 in 2020). © 2023 Wolters Kluwer Medknow Publications. All rights reserved.
Related Docs
View other Related Docs
1. Cost-Effectiveness and Cost-Utility Analysis of Otc Use of Simvastatin 10 Mg for the Primary Prevention of Myocardial Infarction in Iranian Men, DARU, Journal of Pharmaceutical Sciences (2015)
2. Evaluating the Impact of a Clinical Breast Examination Screening Program Within the Irapen Project, Asian Pacific Journal of Cancer Prevention (2024)
3. Establishment of Health Clinics As Mass Screening and Referral Systems for Chronic Non-Communicable Diseases in Primary Health Care, International Journal of Preventive Medicine (2012)
Experts (# of related papers)
View all Related Experts
Bijan Iraj (2)
Farzaneh Mohammadi-Sefiddashti (2)
Other Related Docs
4. Quality of Care for First-Degree Relatives of Type 2 Diabetes Patients Diagnosed With Diabetes at a Screening Program One Year After Diagnosis, Review of Diabetic Studies (2008)
5. Coronary Bypass Surgery Versus Percutaneous Coronary Intervention: Cost-Effectiveness in Iran: A Study in Patients With Multivessel Coronary Artery Disease, International Journal of Technology Assessment in Health Care (2014)
6. The Direct Medical Costs of Outpatient Cares of Type 2 Diabetes in Iran: A Retrospective Study, International Journal of Preventive Medicine (2016)
7. Assessment of Caring Status for Patients With Type 2 Diabetes in Under Control Health Centers of Jarghoyee Region in Isfahan, Iran, Journal of Isfahan Medical School (2017)
8. Strategic Purchasing and the Performance of Health-Care Systems in Upper Middle Income Countries: A Comparative Study, Journal of Education and Health Promotion (2021)
9. The Effect of Quality of Care on Cardiovascular Risk Factors in Newly Diagnosed Diabetic Patients, International Journal of Preventive Medicine (2014)
10. Cost-Utility Analysis of Combination Medical Therapies in Chronic Coronary Syndrome: A Comparative Study Using Real-World and Patient-Level Data From Iran, BMJ Open (2025)
11. A Scoping Review of Possible Solutions for Decreasing Socioeconomic Inequalities in Type 2 Diabetes Mellitus, International Journal of Preventive Medicine (2024)
12. Prescription and Nonprescription Drug Use in Isfahan, Iran: An Observational, Cross-Sectional Study, Current Therapeutic Research - Clinical and Experimental (2008)
13. Estimating Out-Of-Pocket Payments Among Iranian Women With Breast Cancer, International Journal of Cancer Management (2023)
14. Evaluation of the Finnish Diabetes Risk Score (Findrisc) As a Screening Tool for the Metabolic Syndrome, The review of diabetic studies : RDS (2013)
15. Availability and Affordability of Essential Medicines for Diabetes Across High-Income, Middle-Income, and Low-Income Countries: A Prospective Epidemiological Study, The Lancet Diabetes and Endocrinology (2018)
16. Finnish Diabetes Risk Score to Predict Type 2 Diabetes in the Isfahan Diabetes Prevention Study, Diabetes Research and Clinical Practice (2013)
17. The Assessment of Family Physicians' Performance in Screening of Hypertension and Diabetes Mellitus in Rural Areas of Isfahan County: A 5-Year Survey, Journal of Isfahan Medical School (2012)
18. Metabolic Risk Factors Attributed Burden in Iran at National and Subnational Levels, 1990 to 2019, Frontiers in Public Health (2023)
19. Private and Social Time Preference for Health Outcomes: A General Population Survey in Iran, PLoS ONE (2019)
20. The Use and the Cost of Outpatient Diagnostic Procedures for Cardiovascular Diseases in Isfahan Province: A Utilization Study, Journal of Education and Health Promotion (2022)